A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Inclusion Criteria:

• Have a phosphorylated tau (P-tau) result consistent with the presence of amyloidpathology.

• Have a reliable study partner and backup study partner familiar with overallfunction and behavior, such as day-to-day activities and cognitive abilities.

• Have adequate literacy, vision, and hearing for neuropsychological testing atscreening.

• Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitiveimpairment.

• Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimalfunctional impairment.

• If currently receiving medications as symptomatic treatment for AD, dose has beenstable for at least 30 days before screening.

Exclusion Criteria:

• Have dementia or significant other neurological disease that can affect cognition.

• Have current serious or unstable illnesses that in the investigator's opinion, couldinterfere with the analyses of the study.

• Have a history of cancer that, in the investigator's opinion, has a high risk ofrecurrence.

• Have a history of clinically significant multiple or severe drug allergies, orhypersensitivity reactions.

• Have a clinically important laboratory test result or other abnormality asdetermined by investigator, prior to randomization, that could be detrimental to theparticipant or could compromise the study.

• Have any contraindications for magnetic resonance imaging (MRI).

• Have a centrally read MRI that does not meets study entry criteria.

Prior or Current Therapies

• Have ever had prior treatment with a passive anti-amyloid immunotherapy.

• Have received active immunization against Aβ in any other study.